CD8A and neoplasm: Human tumor-derived CD8+ T cells often coexpress TIM-3 and PD-1, and preclinical studies in several murine tumor models demonstrated that the combination of TIM-3 and PD1 blocking antibodies can significantly increase the reversal of T-cell exhaustion.